Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

21P - OX401, a new generation of PARP-interfering drug for cancer treatment

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Wael Jdey

Citation

Annals of Oncology (2020) 31 (suppl_1): S10-S13. 10.1016/annonc/annonc85

Authors

W. Jdey, V. Hayes, C. Zandanel, V. Trochon-Joseph, F. Bono

Author affiliations

  • R&d, Onxeo, 75015 - Paris/FR
More

Resources

Abstract 21P

Onxeo has pioneered a radically new approach of anti-cancer treatment to tackle emergence of resistance: the decoy agonist mechanism of action (MoA). Drugs based on this unprecedented MoA hijack and hyper activate therapeutic targets (decoy effect) leading to exhaustion (agonist effect). This breakthrough MoA has already shown, using our lead compound AsiDNA, target engagement and excellent safety profile in humans and importantly lack of resistance in multiple preclinical studies. These exciting results led us to develop a proprietary platform of oligonucleotides (platON) with decoy agonist properties: the new generation product OX401 targeting PARP, a target already validated in oncology.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings